1-20 of 24
E Carrasco
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P5-12-03: Genome copy number entropy as predictor of response for neoadjuvant therapy in early breast cancer

E Alba, OM Rueda, A Lluch, J Albanell, S-F Chin, JI Chacón, L Calvo, J De la Haba-Rodriguez, B Bermejo, N Ribelles, P Sánchez-Rovira, A Plazaola, A Barnadas, B Cirauqul, M Ramos, A Arcusa, E Carrasco, J Herranz, M Chiesa, R Caballero, A Santonja, F Rojo, C Caldas
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): P5-12-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-P5-12-03
Published: 15 February 2019
View article
Journal Articles

Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer

M Martín, CH Barrios, L Torrecillas, M Ruiz-Borrego, J Bines, J Segalla, A Ruiz, JA García-Sáenz, R Torres, J de la Haba, E García, HL Gómez, A Llombart, M Rodríguez de la Borbolla, JM Baena, A Barnadas, L Calvo, L Pérez-Michel, M Ramos, J Castellanos, A Rodríguez-Lescure, J Cárdenas, J Vinholes, E Martínez de Dueñas, MJ Godes, MA Seguí, A Antón, P López-Álvarez, J Moncayo, G Amorim, E Villar, S Reyes, C Sampaio, B Cardemil, MJ Escudero, S Bezares, E Carrasco, A Lluch
Journal: Cancer Research
Cancer Res (2019) 79 (4_Supplement): GS2-04.
DOI: https://doi.org/10.1158/1538-7445.SABCS18-GS2-04
Published: 15 February 2019
View article
Journal Articles

Abstract P5-21-23: Evaluation of the drug interaction potential of palbociclib and exemestane – Results from the PEARL pharmacokinetic sub-Study

M Martín, J Hoffman, M Ruiz-Borrego, M Muñoz, L Calvo, P Crownover, JA García-Sáenz, E Alba, D Wang, C Thallinger, A Stradella, Á Montaño, B Adamo, S Antolín, F Moreno-Antón, C Falo, V Ruiz, N Martín, R Caballero, E Carrasco, M Gil-Gil
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P5-21-23.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P5-21-23
Published: 15 February 2018
View article
Journal Articles

Abstract OT1-01-02: A multicenter phase II trial to evaluate the efficacy and safety of pembrolizumab and gemcitabine in patients with HER2-negative advanced breast cancer: GEICAM/2015-04 PANGEA-Breast

L de la Cruz, V Sánchez-Margalet, P Berraondo, S Benito, MJ Escudero, R Caballero, E Carrasco, L Galluzzi, F Rojo
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): OT1-01-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-OT1-01-02
Published: 15 February 2018
View article
Journal Articles

Abstract P3-09-08: Overeating and breast cancer risk by pathologic subtypes: EpiGEICAM study

M Pollán, A Castelló, M Martín, A Ruiz, AM Casas, JM Baena, S Antolin, M Ramos, JA Garcia-Saénz, M Muñoz, A Lluch, A de Juan, C Jara, P Sánchez Rovira, A Antón, JI Chacón, A Arcusa, MA Jimeno, S Bezares, E Carrasco, B Pérez-Gómez, V Lope
Journal: Cancer Research
Cancer Res (2018) 78 (4_Supplement): P3-09-08.
DOI: https://doi.org/10.1158/1538-7445.SABCS17-P3-09-08
Published: 15 February 2018
View article
Journal Articles

Abstract OT2-01-21: Phase 2 study of investigational TORC1/2 inhibitor TAK-228 with fulvestrant in women with ER-positive/HER2-negative advanced or metastatic breast cancer that has progressed during or after aromatase inhibitor therapy

JA García-Sáenz, E Carrasco, ML Kneissl, F Zohren, M Martin
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): OT2-01-21.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-OT2-01-21
Published: 15 February 2017
View article
Journal Articles

Abstract OT2-01-06: Phase III study of p albociclib (PD-0332991) in combination with e ndocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with r esistance to a romatase inhibitors. “The PEARL study” (GEICAM/2013-02)

M Martín, Z Kahan, E Carrasco, CH Bartlett, M Casas, M Gil-Gil, M Muñoz, EM Ciruelos, M Ruiz-Borrego, M Margelí, A Antón, B Bermejo, S Morales, E Gal-Yam, M Koehler, JA García-Sáenz, J de la Haba, I Chacón, C Zielinski
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): OT2-01-06.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-OT2-01-06
Published: 15 February 2017
View article
Journal Articles

Abstract OT3-02-07: A phase II study to compare fulvestrant (F) 500mg plus placebo versus (vs) F 500mg plus palbociclib (P) as first line treatment for postmenopausal women with hormone receptor (HR)-positive advanced breast cancer (BC) sensitive to endocrine therapy (ET). “The FLIPPER study” (GEICAM/2014-12)

F Moreno, N Martínez-Jañez, I Garau, JA Guerra, J Alarcón, B Bermejo, L Gonzalez-Cortijo, C Bueno, J Lao, S Bezares, L Rosell, A Blanch, R Caballero, E Carrasco, F Rojo, M Martín, M O'Connor, A Hernando, J Albanell
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): OT3-02-07.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-OT3-02-07
Published: 15 February 2017
View article
Journal Articles

Abstract P4-21-16: Phase III trial to evaluate patient´s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07)

EM Ciruelos, Á Montaño, CA Rodríguez, E González-Flores, A Lluch, L Garrigós, V Quiroga, A Antón, D Malón, JI Chacón, M Velasco, L Gonzalez-Cortijo, L Jolis, T Pascual, Y Amigo, M Casas, MC Cámara, E Carrasco, A Casas
Journal: Cancer Research
Cancer Res (2017) 77 (4_Supplement): P4-21-16.
DOI: https://doi.org/10.1158/1538-7445.SABCS16-P4-21-16
Published: 15 February 2017
View article
Journal Articles

Abstract P3-07-42: Predicting outcome and benefit to first-line bevacizumab in advanced/metastatic hormone receptor (HR)+/HER2-negative breast cancer (BC) treated with endocrine therapy: A correlative science study from the LEA phase III clinical trial (GEICAM/2006-11_GBG 051)

A Prat, J de la Haba-Rodriguez, Á Guerrero, JA García-Sáenz, S Morales, A Antón, M Muñoz, M Ramos, N Martínez-Jáñez, M Margelí, S Servitja, F Rojo, P Galván, S González, J Cruz, P Sánchez-Rovira, A Perelló, C Rodríguez-Martin, M Casas, E Carrasco, R Caballero, M Martín
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): P3-07-42.
DOI: https://doi.org/10.1158/1538-7445.SABCS15-P3-07-42
Published: 15 February 2016
View article
Journal Articles

Abstract P6-05-02: Intrinsic subtype and gene expression changes between primary and metastatic breast cancer

A Prat, E Martínez de Dueñas, P Galván, S Garcia, O Burgués, L Paré, S Antolín, R Martinello, I Blancas, B Adamo, Á Guerrero, M Muñoz, P Nuciforo, M Vidal, RM Pérez, JI Chacón, R Caballero, P Gascón, E Carrasco, F Rojo, CM Perou, J Cortés, V Adamo, J Albanell, A Lluch
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): P6-05-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS15-P6-05-02
Published: 15 February 2016
View article
Journal Articles

Abstract OT3-01-03: Phase III clinical trial to evaluate patient's preference for subcutaneous (SC) versus intravenous (IV) trastuzumab administration in patients with HER2 positive, advanced breast cancer (ABC) under IV trastuzumab treatment for at least 4 months and without disease progression. ChangHER-SC study (GEICAM/2012-07)

E Ciruelos, E González, A Lluch, L Garrigós, V Quiroga, A Antón, T Pascual, Á Montaño, MdM Angulo, MdC Cámara, Y Amigo, E Carrasco, A Casas
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): OT3-01-03.
DOI: https://doi.org/10.1158/1538-7445.SABCS15-OT3-01-03
Published: 15 February 2016
View article
Journal Articles

Abstract OT3-01-02: A phase I-II trial of dasatinib in combination with trastuzumab (T) and paclitaxel in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients: GEICAM/2010-04

A Ocaña, M Ruiz Borrego, M Gil-Martín, S Antolín, Á Guerrero, L Vidal Boixader, M Martín, JM Trigo Pérez, F Rojo, Y Jerez, M Atienza, S Pernas, A Hernando, E Carrasco, S Benito, R Caballero, A Pandiella
Journal: Cancer Research
Cancer Res (2016) 76 (4_Supplement): OT3-01-02.
DOI: https://doi.org/10.1158/1538-7445.SABCS15-OT3-01-02
Published: 15 February 2016
View article
Journal Articles

Abstract P2-11-06: Comparison of PAM50 risk of recurrence (ROR) scores with EndoPredict for predicting risk of distant metastasis in ER+/HER2-, early node-positive breast cancer patients treated with adjuvant chemotherapy - A GEICAM/ 9906 sub-study

M Martin, JC Brase, CM Perou, A Ruiz, A Prat, KE Weber, L Calvo, C Petry, PS Bernard, M Ruiz-Borrego, R Kronenwett, AM Santaballa, CA Rodriguez, IM Alvarez, MA Segui, M Casas, E Carrasco, R Caballero, A Rodriguez-Lescure
Journal: Cancer Research
Cancer Res (2013) 73 (24_Supplement): P2-11-06.
DOI: https://doi.org/10.1158/0008-5472.SABCS13-P2-11-06
Published: 15 December 2013
View article
Journal Articles

Abstract P3-10-02: The BOMET-QOL questionnaire in patients with breast cancer and bone metastasis: The prospective MABOMET study from the Spanish breast cancer research group (GEICAM)

S Del Barco, M Muñoz, M Margeli, JI Chacon, J Cassinello, S Antolin, E Adrover, M Ramos-Vazquez, E Carrasco, MA Jimeno, B Ojeda, X Gonzalez, S Gonzalez, M Constenla, J Florian, A Miguel, A Llombart, A Lluch, M Ruiz-Borrego, R Colomer, A Barnadas
Journal: Cancer Research
Cancer Res (2013) 73 (24_Supplement): P3-10-02.
DOI: https://doi.org/10.1158/0008-5472.SABCS13-P3-10-02
Published: 15 December 2013
View article
Journal Articles

Abstract P3-14-15: Nabrax: Neoadjuvant therapy of breast cancer with weekly nab-paclitaxel: Final safety of GEICAM 2011-02

M Martin, S Antolin, A Anton, A Plazaola, E Garcia-Martinez, MA Segui, P Sanchez-Rovira, C Esteban, E Garcia-Valdes, L Calvo, M Quindos, E Carrasco, C Rodriguez-Martin, JI Chacon
Journal: Cancer Research
Cancer Res (2013) 73 (24_Supplement): P3-14-15.
DOI: https://doi.org/10.1158/0008-5472.SABCS13-P3-14-15
Published: 15 December 2013
View article
Journal Articles

Abstract OT3-1-06: CIBOMA/2004-01_GEICAM/2003-11: A randomised phase III trial assessing adjuvant capecitabine (Cap) maintenance therapy after standard chemotherapy for triple-negative early breast cancer (EBC)

CE Barrios, A Lluch, M Ruiz-Borrego, J Bines, L Torrecillas, E Carrasco, JGM Segalla, A Ruiz, JA Garcia-Saenz, R Torres, J De la Haba-Rodriguez, E Garcia-Martinez, S Morales, H Gomez, J Salvador-Bofill, A Hernando, M Martin
Journal: Cancer Research
Cancer Res (2013) 73 (24_Supplement): OT3-1-06.
DOI: https://doi.org/10.1158/0008-5472.SABCS13-OT3-1-06
Published: 15 December 2013
View article
Journal Articles

Abstract P3-15-02: A prospective, open label, non-comparative trial to determine the incidence of chemotherapy-induced nausea and vomiting associated with the docetaxel-cyclophosphamide regimen in early breast cancer patients. Results from the GEICAM 2009-02 study

V Carañana, M Ramos, E Damau, JA García-Saenz, X González, L Murillo, L Calvo, S Morales, A González-Farré, LA Fernández-Morales, E Carrasco, MI Casas, MdM Angulo, MC Cámara, AI García, A Llombart, C Jara
Journal: Cancer Research
Cancer Res (2013) 73 (24_Supplement): P3-15-02.
DOI: https://doi.org/10.1158/0008-5472.SABCS13-P3-15-02
Published: 15 December 2013
View article
Journal Articles

Abstract S1-7: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer – First efficacy results from the LEA study.

M Martin, S Loibl, G von Minckwitz, S Morales, C Crespo, A Anton, A Guerrero, B Aktas, W Schoenegg, M Muñoz, JA Garcia-Saenz, M Gil, M Ramos, E Carrasco, C Liedtke, G Wachsmann, K Mehta, JR De la Haba, GEICAM (Spanish Breast Cancer Research Group), GBG (German Breast Group)
Journal: Cancer Research
Cancer Res (2012) 72 (24_Supplement): S1-7.
DOI: https://doi.org/10.1158/0008-5472.SABCS12-S1-7
Published: 15 December 2012
View article
Journal Articles

Abstract P2-10-11: Prognostic performance of the EndoPredict score in node-positive chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM/9906 trial.

M Martin, JC Brase, M Ruiz-Borrego, K Krappmann, B Munarriz, K Fisch, A Ruiz, KE Weber, C Crespo, C Petry, CA Rodriguez, R Kronenwett, L Calvo, E Alba, E Carrasco, M Casas, R Caballero, A Rodriguez-Lescure
Journal: Cancer Research
Cancer Res (2012) 72 (24_Supplement): P2-10-11.
DOI: https://doi.org/10.1158/0008-5472.SABCS12-P2-10-11
Published: 15 December 2012
View article